<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611529</url>
  </required_header>
  <id_info>
    <org_study_id>2020-12418</org_study_id>
    <nct_id>NCT04611529</nct_id>
  </id_info>
  <brief_title>Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.</brief_title>
  <official_title>A Randomized Study of Topical Diclofenac Versus Oral Ibuprofen for Acute Non-radicular Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind study comparing two different treatments for acute low&#xD;
      back pain, oral ibuprofen and topical diclofenac. Participants will be randomized to one of&#xD;
      three study arms: 1) Oral ibuprofen + topical diclofenac; 2) Oral ibuprofen + topical&#xD;
      placebo; 3) Oral placebo + topical diclofenac. We will determine outcomes 2 days later.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Roland Morris Disability Questionnaire</measure>
    <time_frame>48 hours</time_frame>
    <description>The Roland-Morris is a 24-item self-report questionnaire about how low-back pain affects functional activities. Each question is worth one point so scores can range from 0 (no disability) to 24 (severe disability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Moderate or severe low back pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Participants will be asked to describe their worst pain over the previous 24 hours using the terms severe, moderate, mild, or none</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of medication for low back pain</measure>
    <time_frame>48 hours</time_frame>
    <description>Participants will be asked if they used any medication for low back pain in the previous 24 hours</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Oral ibuprofen + topical diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ibuprofen 400mg Topical diclofenac 2gm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ibuprofen + topical placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ibuprofen 400mg Topical placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral placebo + topical diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral placebo Topical diclofenac 2gm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 400 mg</intervention_name>
    <description>Ibuprofen 400mg</description>
    <arm_group_label>Oral ibuprofen + topical diclofenac</arm_group_label>
    <arm_group_label>Oral ibuprofen + topical placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical diclofenac</intervention_name>
    <description>Diclofenac 1% gel 4gm</description>
    <arm_group_label>Oral ibuprofen + topical diclofenac</arm_group_label>
    <arm_group_label>Oral placebo + topical diclofenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present to ED primary for management of LBP, defined as pain originating between the&#xD;
             lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain&#xD;
             originating from tissues lateral to the paraspinal muscles, will not be included.&#xD;
&#xD;
          -  Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies&#xD;
             such as urinary tract infection, ovarian cysts, or influenza like illness will be&#xD;
             excluded. The primary clinical diagnosis, at the conclusion of the ED visit, must be a&#xD;
             diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.&#xD;
&#xD;
          -  Patient is to be discharged home.&#xD;
&#xD;
          -  Age 18-69 Enrollment will be limited to adults younger than 70 years because of the&#xD;
             increased risk of adverse medication effects in the elderly.&#xD;
&#xD;
          -  Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal&#xD;
             folds in a radicular pattern.&#xD;
&#xD;
          -  Pain duration &lt;2 weeks (336 hours).&#xD;
&#xD;
          -  Prior to the acute attack of LBP, back pain must occur less frequently than once per&#xD;
             month.&#xD;
&#xD;
          -  Non-traumatic LBP: no substantial and direct trauma to the back within the previous&#xD;
             month&#xD;
&#xD;
          -  Functionally impairing back pain: A baseline score of &gt; 5 on the Roland-Morris&#xD;
             Disability Questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not available for follow-up&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Any analgesic medication use on a daily or near-daily basis&#xD;
&#xD;
          -  Allergic to or intolerant of investigational medications&#xD;
&#xD;
          -  Open wounds or skin breakdown of the lower back&#xD;
&#xD;
          -  Contra-indications to investigational medications: 1) known peptic ulcer disease,&#xD;
             chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure (NYHA&#xD;
             2 or worse) 3) Chronic kidney disease (GFR &lt;60ml/min) 4) Current use of&#xD;
             anti-coagulants 5) cirrhosis (Child Pugh A or worse) or hepatitis (transaminases 2x&#xD;
             the upper limit of normal)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin W Friedman, MD</last_name>
    <phone>7189206626</phone>
    <email>befriedm@montefiore.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Friedman, MD</last_name>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

